4.8 Article

IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from γδ T Cells

Journal

CELL REPORTS
Volume 27, Issue 3, Pages 835-+

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2019.03.082

Keywords

-

Categories

Funding

  1. Else Kroner-Fresenius Foundation (EKFS)
  2. Deutsche Krebshilfe [70112451]
  3. Landesoffensive zur Entwicklung wissenschaftlich-okonomischer Exzellenz (LOEWE
  4. LOEWE Center for Translational Medicine and Pharmacology)
  5. Deutsche Forschungsgemeinschaft (DFG) [GRK2336, SFB1039, FOR2438]
  6. China Scholarship Council (CSC)

Ask authors/readers for more resources

Interleukin-38 (IL-38) is a cytokine of the IL-1 family with a role in chronic inflammation. However, its main cellular targets and receptors remain obscure. IL-38 is highly expressed in the skin and downregulated in psoriasis patients. We report an investigation in cellular targets of IL-38 during the progression of imiquimod-induced psoriasis. In this model, IL-38 knockout (IL-38 KO) mice show delayed disease resolution with exacerbated IL-17-mediated inflammation, which is reversed by the administration of mature IL-38 or gamma delta T cell-receptor-blocking antibodies. Mechanistically, X-linked IL-1 receptor accessory protein-like 1 (IL1RAPL1) is upregulated upon gamma delta T cell activation to feedforward-amplify IL-17 production and is required for IL-38 to suppress gamma delta T cell IL-17 production. Accordingly, psoriatic IL1RAPL1 KO mice show reduced inflammation and IL-17 production by gamma delta T cells. Our findings indicate a role for IL-38 in the regulation of gamma delta T cell activation through IL1RAPL1, with consequences for auto-inflammatory disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available